IRIS Accounts Production v24.2.0.383 10524404 Board of Directors 1.1.23 31.12.23 31.12.23 0 0 false true false false true false Fair value model Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh105244042022-12-31105244042023-12-31105244042023-01-012023-12-31105244042021-12-31105244042022-01-012022-12-31105244042022-12-3110524404ns15:EnglandWales2023-01-012023-12-3110524404ns14:PoundSterling2023-01-012023-12-3110524404ns10:Director12023-01-012023-12-3110524404ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3110524404ns10:SmallEntities2023-01-012023-12-3110524404ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3110524404ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3110524404ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3110524404ns10:FullAccounts2023-01-012023-12-3110524404ns10:OrdinaryShareClass12023-01-012023-12-3110524404ns10:Director22023-01-012023-12-3110524404ns10:RegisteredOffice2023-01-012023-12-3110524404ns5:CurrentFinancialInstruments2023-12-3110524404ns5:CurrentFinancialInstruments2022-12-3110524404ns5:Non-currentFinancialInstruments2023-12-3110524404ns5:Non-currentFinancialInstruments2022-12-3110524404ns5:ShareCapital2023-12-3110524404ns5:ShareCapital2022-12-3110524404ns5:RetainedEarningsAccumulatedLosses2023-12-3110524404ns5:RetainedEarningsAccumulatedLosses2022-12-3110524404ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-3110524404ns5:WithinOneYearns5:CurrentFinancialInstruments2022-12-3110524404ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2023-12-3110524404ns5:BetweenOneTwoYearsns5:Non-currentFinancialInstruments2022-12-3110524404ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-12-3110524404ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2022-12-3110524404ns5:Secured2023-12-3110524404ns5:Secured2022-12-3110524404ns5:DeferredTaxation2022-12-3110524404ns5:DeferredTaxation2023-12-3110524404ns10:OrdinaryShareClass12023-12-3110524404ns5:RetainedEarningsAccumulatedLosses2022-12-3110524404ns5:RetainedEarningsAccumulatedLosses2023-01-012023-12-31
REGISTERED NUMBER: 10524404 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023

FOR

RADPHARM PROPERTY INVESTMENTS LIMITED

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


RADPHARM PROPERTY INVESTMENTS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2023







DIRECTORS: S Iqbal
Mrs A Iqbal



REGISTERED OFFICE: 2 Cedargrove
Hagley
Stourbridge
West Midlands
DY9 0DR



REGISTERED NUMBER: 10524404 (England and Wales)



ACCOUNTANTS: Ashcrofts Accountants Limited
2 Cedargrove
Hagley
Stourbridge
West Midlands
DY9 0DR



BANKERS: Barclays Bank plc
51 Mosley Street
Manchester
M60 2AU

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

BALANCE SHEET
31 DECEMBER 2023

2023 2022
Notes £    £   
FIXED ASSETS
Investment property 4 591,950 591,950

CURRENT ASSETS
Debtors 5 - 1,790
Cash at bank 138,839 91,316
138,839 93,106
CREDITORS
Amounts falling due within one year 6 (467,422 ) (472,255 )
NET CURRENT LIABILITIES (328,583 ) (379,149 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

263,367

212,801

CREDITORS
Amounts falling due after more than one
year

7

(226,058

)

(196,901

)
NET ASSETS 37,309 15,900

CAPITAL AND RESERVES
Called up share capital 11 100 100
Retained earnings 12 37,209 15,800
SHAREHOLDERS' FUNDS 37,309 15,900

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

BALANCE SHEET - continued
31 DECEMBER 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 September 2024 and were signed on its behalf by:





S Iqbal - Director


RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023


1. STATUTORY INFORMATION

Radpharm Property Investments Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2022 - NIL).

4. INVESTMENT PROPERTY
Total
£   
FAIR VALUE
At 1 January 2023
and 31 December 2023 591,950
NET BOOK VALUE
At 31 December 2023 591,950
At 31 December 2022 591,950

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023


5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors - 571
Deferred tax asset - 1,219
- 1,790

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Bank loans and overdrafts (see note 8) - 7,844
Trade creditors 733 1,717
Corporation tax 3,803 -
Other creditors 369,564 369,564
Directors' loan accounts 92,589 92,397
Accruals and deferred income 733 733
467,422 472,255

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2023 2022
£    £   
Bank loans (see note 8) 226,058 196,901

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 226,058 161,325

8. LOANS

An analysis of the maturity of loans is given below:

2023 2022
£    £   
Amounts falling due within one year or on demand:
Bank loans - 7,844

Amounts falling due between one and two years:
Bank loans - 1-2 years - 8,444

Amounts falling due between two and five years:
Bank loans - 2-5 years - 27,132

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 226,058 161,325

RADPHARM PROPERTY INVESTMENTS LIMITED (REGISTERED NUMBER: 10524404)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023


9. SECURED DEBTS

The following secured debts are included within creditors:

2023 2022
£    £   
Bank loans 226,058 204,745

10. DEFERRED TAX
£   
Balance at 1 January 2023 (1,219 )
Charged during the year 1,219
Balance at 31 December 2023 -

11. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
100 Ordinary £1 100 100

12. RESERVES
Retained
earnings
£   

At 1 January 2023 15,800
Profit for the year 21,409
At 31 December 2023 37,209

13. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

At 31 December 2023 there was a loan from Mr S Iqbal of £92,589 (2022: £92,397). This unsecured loan is interest free and repayable on demand.

14. RELATED PARTY DISCLOSURES

At 31 December 2023, there was a loan from Radcliffe Pharmacy Limited of £363,564 (2022: £363,564), a company in which Mr S Iqbal is a director. This unsecured loan is interest free and repayable on demand.